Neoplastic Process – Page 2

Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia

2 weeks ago talkbio0Tagged Eisai, licensing agreement, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Nuvation Bio, ROS1 gene, taletrectinib

Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

2 weeks ago talkbio0Tagged annamycin, Clinical Trials, Leukemia, Myelocytic, Acute, milestones, MIRACLE trial, Moleculin, WP1066

Moleculin; MIRACLE trial; Annamycin; WP1066; AML; clinical trials; 2026 milestones

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

2 weeks ago talkbio0Tagged ASCO GI 2026, CAR-T, Claudin-18 Isoform A2, IMC002, Immunofoco, In complete remission, Malignant neoplasm of stomach, ORR

Immunofoco; IMC002; ASCO GI 2026; CAR-T; CLDN18.2; gastric cancer; complete response; ORR

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

2 weeks ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Neoplasms, PD-1/VEGF, RC148, RemeGen

AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

2 weeks ago talkbio0Tagged Aktis, AKTS, Biotech IPOs, bounce, Capital Markets, CD276 gene, Eli Lilly backing, IPO, NECTIN4 gene, Neoplasms, Radiopharmaceuticals, Window (physical object)

Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

2 weeks ago talkbio0Tagged AbbVie, Acquisition, daraxonrasib, financial, J.P. Morgan Healthcare Conference, Merck, Neoplasms, RAS-driven cancers, Revolution Medicines, rumors, RVMD, takeover talks, Wall Street Journal

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Roche returns to Chinese biotech MediLink for another ADC pact

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, China, Neoplasms, Platform, Roche (company), Small cell carcinoma of lung, small-cell lung cancer, Solid Neoplasm, therapeutic autologous dendritic cells, TMALIN, YL201

Roche; MediLink Therapeutics; YL201; antibody-drug conjugate; ADC; B7-H3; TMALIN platform; small-cell lung cancer; SCLC; solid tumors; licensing deal; oncology; China biotech

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

2 weeks ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

2 weeks ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

2 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson